Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients

被引：45
作者：
Hans, Sophie [1 ]
Cottu, Paul [1 ]
Kirova, Youlia M. [1 ]
机构：
[1] Inst Curie, Paris, France
来源：
RADIOTHERAPY AND ONCOLOGY | 2018年 / 126卷 / 01期
关键词：
D O I：
10.1016/j.radonc.2017.09.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：181 / 181
页数：1
相关论文
共 2 条
  • [1] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
    Cristofanilli, Massimo
    Turner, Nicholas C.
    Bondarenko, Igor
    Ro, Jungsil
    Im, Seock-Ah
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Loi, Sherene
    Verma, Sunil
    Iwata, Hiroji
    Harbeck, Nadia
    Zhang, Ke
    Theall, Kathy Puyana
    Jiang, Yuqiu
    Bartlett, Cynthia Huang
    Koehler, Maria
    Slamon, Dennis
    [J]. LANCET ONCOLOGY, 2016, 17 (04) : 425 - 439
  • [2] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
    Finn, Richard S.
    Crown, John P.
    Lang, Istvan
    Boer, Katalin
    Bondarenko, Igor M.
    Kulyk, Sergey O.
    Ettl, Johannes
    Patel, Ravindranath
    Pinter, Tamas
    Schmidt, Marcus
    Shparyk, Yaroslav
    Thummala, Anu R.
    Voytko, Nataliya L.
    Fowst, Camilla
    Huang, Xin
    Kim, Sindy T.
    Randolph, Sophia
    Slamon, Dennis J.
    [J]. LANCET ONCOLOGY, 2015, 16 (01) : 25 - 35
1